Nuria Coll Bastus — Trial Matching in 5 Minutes & Why 80% of Trials Are Delayed

Adam Walker:I'm Adam Walker, a biometrics consultant, and this is the Pharma Prescribed Podcast where leaders, innovators, and hidden voices in healthcare open up, no sound bites, no spin, just raw insight, one prescription at a time. In an industry driven by data protocols and pressure, we rarely pause to ask the human questions.

Adam Walker:What drives us? What breaks us and what truths live behind the titles we wear?

Adam Walker:Noria called BAAs is an industry disruptor whose roots in academic research and onco genomics have blossomed into a bold new vision for clinical trials. Born in Spain and now based in the uk. Noria brings a cross-cultural lens to one of farmer's most persistent challenges.

Adam Walker:Patient recruitment. With over 12 years in drug development and a background in Onco genomics, clinical net is a health tech startup she founded to match patients with trials in under five minutes. Globally, 80% of clinical trials are delayed due to recruitment issues. Costing billions annually RE'S platform is challenging that automating access, centralizing data, and empowering both patients and practitioners.

Adam Walker:Nuria, great to see you today. Welcome to Pharma Prescribed.

Nuria Coll Bastus:Thank you very much. Nice to meet you.

Adam Walker:So for our listeners, perhaps you could give us a little bit of background as to how you got into the industry and a little bit more about clinical net.

Nuria Coll Bastus:Yes, so my background is in science, and as you explain, I did my bachelor degree in chemistry, uh, in Barcelona.

Nuria Coll Bastus:Then I did a couple of masters, one in organic chemistry, and then I switched to cancer therapeutics. I wanted to have more background on biotechnology, which was my passion. After that, I had opportunity to do a PhD in Onco Genomics here in London at pars Cancer Institute. And I have to say that I love it.

Nuria Coll Bastus:I, I, I love all the experience of research and, and learning about cancer and its its courses. Um, but eventually I made the, the decision to move industry to, to work in pharma and biotech. I work in a range of.

Nuria Coll Bastus:Different organizations from a small to weak, uh, lead pharmacy in, in, in the industry and is what I came across the problem that clinical net is trying to solve, because I was working in pharma and my family and friends knew about it every time that they had somebody in their network that had, uh, been diagnosed with a, in this case, a cancer that was not treatable, they will reach out to me asking do, since you're work in pharma, do you know of any clinical.

Nuria Coll Bastus:Any clinical trial because the, the doctor told us that there is nothing to do, and the reality was that 60% surveys say that 60% of the people will consider clinical trial in these situations, but. Only 8% end up entering clinical trials. And at the same time I was, I was working in pharma and we were struggling to recruit enough participants, and that is a big, huge problem.

Nuria Coll Bastus:As you said, 80% of the trials experience delays costing billions of dollars or pounds, not only on cost, but also opportunity loss because it eats from the pattern. So I was wondering why there is this disconnect, why there are patients looking for trials and why there are trials that are not. That are, do not have enough patients.

Nuria Coll Bastus:So back then I was doing an MBA on my free time, and I put this as a case study. So I start doing all the surveys and interviews to, uh, with oncologists, patients, patient organizations, my colleagues working in pharma to try to understand why this is happening and which will be the ideal solution. And based on that, I design.

Nuria Coll Bastus:These ideal solutions, which maybe we can talk about it later. And because I did quite a lot of noise with the surveys, uh, n Angel investor in London came my way and offered me to put some money towards building this ideal solution. So he convinced me to leave my job in pharma to, to try to do this possible.

Nuria Coll Bastus:And this is how everything has started.

Adam Walker:Amazing. How long ago was that when this angel investor approached you with this idea?

Nuria Coll Bastus:That was in 2021. I remember. It was a spring. He actually asked me to meet and I say a couple of times, no, uh, eventually I meet him and he made the offer at the beginning of summer.

Nuria Coll Bastus:I took the full summer to think about it, and in September, 2021, I accepted is when I gave my notice to the company was working, and three months later is when I could dedicate full time to start working on it.

Adam Walker:Okay, so. You happened to drop in passing that you just had some spare time and you were doing an MBA that sounds like, uh, quite a heavy lift in itself.

Adam Walker:During that MBA, clearly you were focusing some attention around this particular problem. Can you tell me more about that?

Nuria Coll Bastus:Yes. I spent many years in academia doing degrees, uh, masters and a PhD. But. And I felt I, I had an expertise in science and research, but I did not know much about business.

Nuria Coll Bastus:And as a curious person, I wanted to try to, uh, wanted to understand more that, so I was young and I had plenty of energy and. My, yeah, natural curiosity made me want to do an MBA and for that I had to do a dissertation, uh, test. So I, I put that as the topic because was the biggest, again, the, one of the biggest problems in pharma that I saw, uh, or experience firsthand.

Nuria Coll Bastus:I also thought, uh, were, because the people that were reaching out to me asking for trials were people that are close to me. I could see their suffering and how much hope they need. They were looking for, and it's there. The trials are there, are free, are safe, and many other people will benefit from that as much as.

Nuria Coll Bastus:Trials will benefit from having the data from the patients. So I thought that would, it's a problem that has to be solved and it could have so much value into society, faster approvals of drugs, more treatments, more innovative treatments, accessible right now, not 10 years down the line. So I thought it, if there was a, a way to do it it was worth exploring it.

Nuria Coll Bastus:So that motivation kept me spending my evenings and weekends working on it.

Adam Walker:You've mentioned a number of aspects of interest there for me, particularly referencing how difficult it is for patients to find clinical trials. Is the barrier to entry the knowledge, is it knowing where to go to find those groundbreaking opportunities to connect with specific oncology trials? What is that barrier for patients?

Nuria Coll Bastus:So is yeah, having a place where they can go and find the information in a way that is digestible. So all clinical trial information or the enough clinical trial information to know. Whether there are trials or not available for you or for your patients, if you are the doctor or the nurse, it's there.

Nuria Coll Bastus:It's out there, but it's in a structure and in a format that is not digestible to find, not even for people that speak the medical language, but also for patients they do not understand some of the terminology. Um, there are a small, uh, a smaller database that some patient organizations or other companies put together.

Nuria Coll Bastus:They clean it, they structure it, they make it a bit more digestible, but they tend to miss quite a lot of the trials. So what it end up happening is when patients or try to look for, for trials, they have to navigate through different sites. And again, and one of the things that I checked during my, my MBA was.

Nuria Coll Bastus:How is how people behave and it was sort well surprising. Or one of the interesting things to see is that when people look for information, only 20% of them will look. They will a hundred percent will go and look for that information, and only 20% of them will try and look for a second place. So they give up if they don't find information straight away because of time, because of brain capacity or.

Nuria Coll Bastus:Because they also are, if they are patients, they're going through quite a lot of e emotional burden. So they don't tend to spend hours, uh, looking for it. They give up easily if they don't find, uh, a, a source that they can use.

Adam Walker:So is your goal to, to give simplified information to the patients as much as to give a breadth of understanding to the medical community as well, to share with their patients?

Adam Walker:Is it somewhere between that sweet spot.

Nuria Coll Bastus:Yes. So we want a platform where anybody can go there and within a short period of time, an average five minutes, they can find the most suitable trial for them or their families or their patients in, regardless of who they are. So it's a platform that should be a, is a, a hub, a point of a a, a global point of information from clinical trials that is in.

Nuria Coll Bastus:Lay language as well as medical language. And it's a structure in a way that it's very simple to use. And within five minutes it basically, you find the information for patients and their families because it should be easy uh, uh, and don't add to the burden they are going through already. And for healthcare professionals like doctors and nurses, because they don't, they're already overworked and they don't have more ma, much more than five minutes to look for this information.

Adam Walker:As you were describing that, I was thinking about the technology that must be behind and under the hood of this technology itself, and having worked and developed various platforms myself and supported companies that have done so. Who are the kind of people that you are working with? Are you a software developer?

Adam Walker:I don't think you are, but do you work with software developers? How did this. C creation come to bear.

Nuria Coll Bastus:So yes, I'm not a support developer. Uh, we have a team. So this is a very good question. So when I started, I thought, this is simple, right? We have the clinical care information is available. Well, publicly, we have amazing AI in the, in the last few years.

Nuria Coll Bastus:The only thing you need to do is to take all that information. Plug it through AI and structure it and that's it. Why? No, why this doesn't exist. It's so simple, right? I talked to every single company that back then was doing, was supporting patient recruitment, and none of them were doing what we're doing.

Nuria Coll Bastus:Once I start working on it and I put together the team of developers, I understood why didn't exist is incredibly difficult. So when you get, I gave the problem to three different teams. One in India, one in the us, one in in London. None of them could manage to do it. And when I say teams, I meant AI experts.

Nuria Coll Bastus:And the reason for that is because even today AI is fantastic. Uh, LLMs are great, but they still are, they're not able to process that huge amount of information. We have 65,000 clinical trials open for recruitment and what we had to do. What I did back then is I did a six week course. I was not on ai.

Nuria Coll Bastus:I did not, uh, pretend or expect to become an an expert, but I wanted to understand the limitations of what we can get with ai. When I had that knowledge, like basic what you can do with the different types of ai, I. Come up with a model of how we can break down the clinical trial information so we can process it sequentially through different types of AI in that way.

Nuria Coll Bastus:Uh, from, so breaking it up from a medical perspective, this is why the AI teams were not able to do it because they did not have the medical or experience in clinical trials. So you needed somebody that underst. Then what matters and what don't matter from a clinical trial information point of view.

Nuria Coll Bastus:So when we come up with this model, the only instructions for them was, okay for each of these steps, use this type of AI to to do this, to ex, to structure it in this way. And that is basically the way that we managed to do it.

Adam Walker:Again, following on from that point, I'm thinking about medical dictionaries, unstructured data sets from all over the. All over the place from hospitals, from clinical trials.gov, various other platforms, presumably all being filtered through into clinical net. Yeah. Is that essentially what you've managed to do to simplify that into a funnel?

Nuria Coll Bastus:Yeah, so we are, uh, getting the information from primary registries. But as many people know that information comes. Very unstructured. It's, uh, written by people working in pharma in different ways. So, for example one of the exclusion criteria of a trial could be not being pregnant, and another trial will say exactly the same, but in other words, like having a negative.

Nuria Coll Bastus:HCC test, it's completely worse. You cannot use NLPs. Yes, you can use LLMs, but when you are extrapolating to 65,000 clinical trials, basically we'll start hallucinating and obviously the cost will be, uh, unbearable if you have to do that for every single patient in and that you support. Also, we have all the, all the trials or conditions, so the amount of people or users that we have will make that completely unfeasible from a business perspective.

Nuria Coll Bastus:So yes, we are extracting that information and then we structure it in house.

Adam Walker:Thank you for sharing that and, and explaining that a little bit more. I can understand why that is a very heavy lift and why you might need many different teams.

Adam Walker:So you've overcome that and you now have a working model and patients are.

Adam Walker:And medical doctors are able to access that information in one central place. Is it a subscription model? How does it work? How could I access it, for example, on behalf of friends, family, loved ones?

Nuria Coll Bastus:So the only thing you need to do is to go to the site. So it's an a URL, it's trials dot clinical net.com.

Nuria Coll Bastus:If you arrive to our, uh, website instead, clinical net.com, there are plenty of links everywhere to go to the platform. Anybody can use it for free. You don't even need to register. You start, you can start playing with it at some stage. Uh, after using it for, for a little bit, it's gonna ask you if you want to sign up.

Nuria Coll Bastus:You can reject it. You don't need to. It's not mandatory, but we encourage people to sign up just because if we have their information, if there are new trials, we get, we update the platform, we update the data, the trials, every 24 hours. So it could be that if today you don't find a trial, it could be to tomorrow or next week, there will be a trial that suits you.

Nuria Coll Bastus:So if you register. Apart from having additional features, which is saving to your favorites, we can also let you know if there is any new trial that you may want to consider. But it's, as I said, it's free for everybody to use. You don't even need to register if you don't want. Just bear in mind that of that popup, and then for those that do.

Nuria Coll Bastus:Final trial, they are matched to a trial and they want to go ahead and learn more rec information ab from the trial team or involve their doctors. If it's the patient or the family is doing it, then we ask them obviously to register because we have to send that communication with the contact details.

Nuria Coll Bastus:So that, but ag again, it's at no cost for anybody. So. One of the things that it's very clear, that I made very clear to, to everybody working in the company and to our investors is this is a platform that should be always free for patients charities doctors and for academic trials. So, you know, there are ac trials that are run by academic institutions, university hospitals, for example, and others that are run by.

Nuria Coll Bastus:Profit organizations like, uh, pharmaceuticals and biotechs. I work at in academia, I work in hospitals. I, I work in the, uh, Imperial Trials unit before I moved to industry and I work in, in pharma and biotech. I, and I've been family members of patients that needed trials I know who has the money.

Nuria Coll Bastus:I know who, which are the burden for everybody. And it just is a stretch here in the uk in any other healthcare system, in any country's the same. And so our paying customers are pharma. So as, um, private organizations, trials, at the same time, we know that this is going to work only if everybody have access, including all pharma and biotech.

Nuria Coll Bastus:So we don't want. Financials or cost to be a restriction for pharma. So what we did is we create a model where we can offer the platform in a subscription that is less than 10% the cost of any other recruitment, fa organization out there. The reasons why we are able to do that is because everything is automatic automated.

Nuria Coll Bastus:Again, when I was doing the MBA, I talked to every single recruitment agency in the US and in the uk. When I was, I was shocked about the prices, but they were justified. They had an army of a hundred PhD educated people doing the search of patients or do the manually. We don't have that cost. We don't need to charge half million or 1 million to support the recruitment of a trial because we don't.

Nuria Coll Bastus:It's done automatically and because of that, we can. Go to pharma and ask for a license that is completely affordable for them.

Adam Walker:It's so thought provoking that you've given so much thought to the people that need access. Namely the patients, the families, and the caregivers, and the model centers around pharma companies and biotechs paying for that service.

Adam Walker:During your investigations, I'm assuming you identified, not only was there a gap, but actually there was an opportunity here because it's one thing identifying a gap. It's quite another turning that into a financial opportunity that will also support healthcare. And there are many companies that are in the dust the, that we speak of in, you know, in the past that weren't able to overcome that costing model whereby it was actually sustainable.

Adam Walker:Is this model sustainable? If so, how?

Nuria Coll Bastus:Yes it is. But again, it's, uh, it will only work if everybody's using it because if we do have all farmers, uh, supporting us to receive patients, but patients do not use it, that's not gonna solve the problem. If we have. Millions of patients using us but pharma is not supporting supporting us, is not using us, then we will not be able to connect them to their trials.

Nuria Coll Bastus:So it's, uh, we have three main users. Whoever is looking for the trial, let's call it patient or medical team, the trial teams that are receiving those patients, and then the, what we call a sponsor, which is the basically the owners of the, of the trial as well, which are pharma and biotech. So the three of them are linked to the platform and all of them are, have to be using it to work to basically be able to connect with each other.

Nuria Coll Bastus:So this is why the start is gonna be always. Difficult. It's like, uh, gonna be a, like a snowball. It's gonna be small at the beginning, and the more people use it, the more the everybody else will come.

Adam Walker:So I, I, I'm gonna put my Dragons Den hat on now and ask you, at what point if you're making money at the moment, is this sustainable as a, as a business, as clinical net, a sustainable business?

Adam Walker:Yet, have you repaid some of the money from that angel investor?

Nuria Coll Bastus:So it's very early days. So we, the challenge of creating the platform and structuring the data took us, um, was big enough to take us three years to, to produce a scalable platform. So the first year and a half we managed to have two. To create, uh, to structure all oncology trials, but it was not scalable to everything else.

Nuria Coll Bastus:So it took us in total three years to, to build a platform. Now we are starting to praise awarenesses. So we recently brought on the, into the team, our marketing director, ourselves lead, and we are now starting to raise, uh, some awareness, meaning that we have already some pharmaceutical signing agreements with us and revenues coming.

Nuria Coll Bastus:It's not covering yet the cost, particularly because we want we want to keep in incorporating new features, uh, into the platform to give even a better user experience. So cost of development are still significant, so we expect to start profitable with the current model within nine to 12 months from now.

Adam Walker:I didn't mean to ask that from a point of discomfort, Nuria, it was really from the point of view of. Just understanding where the business is because as I said, having been in and around startup world, I know these things take a long time. There's a lot of effort that goes into that heavy lift at the beginning, and many companies don't get beyond that three years of development, they go to the wall because they've run out of money.

Adam Walker:There's no more runway that they can build upon. So I'm delighted to hear that you are in that next phase. You are recruiting people that are now pushing out that message into the. Public domain because quite clearly there is a requirement for this. You've done a lot of work, a lot of understanding around the key points that you're trying to overcome there.

Adam Walker:So really congratulations on that particular point and I'm, I'm delighted to hear that.

Adam Walker:So you talked about personal connection with this. Are you happy to elaborate a little bit more around that and your own personal story that really drove you because. It's one thing having a startup, it's another having an angel investor, and it's another to take that forward.

Adam Walker:But there has to be something more that drives you. I'm a I'm as I'm guessing there's something more that's driving you.

Nuria Coll Bastus:Yes. And I think I alluded a little bit when I explain how I arrive here, I. I saw the, I saw how much hope, having one more treatment option give to certain families and patients and clinical trials give that.

Nuria Coll Bastus:In regard to my personal stories, I remember two of them, uh, on top of my head. The first one was, well, I was still working in pharma. This former colleague of mine from another company reached out to me saying that. Her husband was recently diagnosed with metastatic SS of, I'm not gonna be able to say it, but basically a type of gastric cancer.

Nuria Coll Bastus:And, uh, the doctor said there was some radiotherapy they could do, but nothing else. And so she was desperate to look for innovative treatments in clinical trials. She said she was spending every day, three six hours looking for. Clinical trials, but she didn't know the language. She was, uh, even though she was work with me, she work in the IT team.

Nuria Coll Bastus:So she was actually educating herself on medical terminology to look for trials. And at some point she gave up and reached out to me. Uh, but then. I look for trials. I online on primary registries, it took me six hours to go through to come out with the list for her husband. And I was used to navigate through clinical trials, was, uh, I was using those sites every day for my job.

Nuria Coll Bastus:So I was thinking, how the hell will anybody do that? First the time and second the knowledge. And when I gave her the list and they went through. The appointments with the doctors. She was, she told me how important, just having that hope, , how much that meant for them. Just knowing that they will maybe have the opportunity to spend one more Christmas together or one more anniversary together.

Nuria Coll Bastus:So that was something that really. Make me realize how is people doing it, why they don't have the same opportunity. And the other example was, uh, when my mother was diagnosed with metastatic melanoma, I took her to one of the best private oncologists in Barcelona in Spain. And by the time that we arrived to that appointment, I already had the search.

Nuria Coll Bastus:I already knew which clinical trials she could go because I was aware that there were some treatments. That were approved in the uk that were very good for melanoma, but were not yet approved in Spain for her particular case. So another way to receive this kind of treatments is to go into clinical trials.

Nuria Coll Bastus:So there were two trials ongoing in Barcelona, and when I arrived to the, we arrested the appointment. One of the final questions was, is there any trial? I mean, my mother cannot access this treatment. It's not available in Spain. Can she go to a trial? And the response of this rename oncologist was don't know of any that is going around.

Nuria Coll Bastus:So when I presented, there are these two running in the nearby hospital, she said, this is very useful. I have a few other patients that may also be eligible. So thank you so much for pointing this out. And these are people that are on the top of their careers and yet do not have the time to look for all this information.

Nuria Coll Bastus:It is like it's. They, and not because they're not interested or they don't care, it's just they don't have the time or the capacity. So at the end that make me realize it's the job of the family and the patients to take care of your own health. You may be very lucky, you end up going to a doctor that just happens to have heard about the trial or themselves.

Nuria Coll Bastus:They run a trial, but that needs a postcode lottery, right? So this is why it was very important to create something that gave power. To patients because doctors and nurses could do it. But also if the patient does it, they have the time and the incentive more than the healthcare providers, they can go to their, uh, to their appointments and say, I saw this trial, should we consider it, , the platform does that, that not only matches with a clinical trial, but also connects you with your medical team. So they send the trial link, and also allows the, the medical team to refer to a proper referral to the, sorry, the medical team of the patient to the, a proper referral into the trial team.

Nuria Coll Bastus:So we basically simplify the full process and then at that step, clinical net steps back once they get in touch. Whatever happens from there in terms of sharing information or, uh, doing all the steps to get formal inside the platform, other trials is obviously up to them.

Adam Walker:That's an amazing insight and thank you for sharing both of those because I think not only will that resonate , with our audience, but also it resonates with me, as a caregiver and someone who's been around family members also who've needed.

Adam Walker:Care at various points in their life. And I think that's really where you've hit the nail on the head there. It's that personal accountability and being able to do something. As you say, if the medical doctor that sat in front of you, and especially this room doesn't have awareness or visibility of these things, then what hope, what hope is there for patients and caregivers.

Adam Walker:It's remarkable. That's a really phenomenal insight that you shared there.

Adam Walker:Moving forward when people are using this tool and it is having an influence over people's care pathways, are you seeing those stories already? Because it really does remind me so much of my experiences in rare disease as well.

Adam Walker:It seems like there's like an overlay between finding trials, finding medications, and connecting those, the dots in between.

Nuria Coll Bastus:Yes. So we already had cases where we had patients entering , these treatments, uh, clinical trials and their family come back to us. Not everybody does come back to us because as I said, they, once we put them in touch, we don't follow them.

Nuria Coll Bastus:Um, but some of them come back to us expressing how grateful they are that we exist and how much hope. We gave to those families and until now I've been talking about those that exhausted all the resources and then they go into trials because they don't know what else to go. But my vision is not to use clinical trials as the last resource because some of them will be on for patients that are just.

Nuria Coll Bastus:Now that if the rest is another treatment, they not may, they may not become a realizable. So the idea is whenever you are diagnosed with something clinical trial should be one more treatment option on the table. You can choose whether to use them or not to use them, but should be from day one.

Nuria Coll Bastus:These are all the treatments that are approved. These are all the treatments that are in clinical trials, which is the best sequence that we can use to optimize all the treatment options. Because if you start with one and that kills three options down the line, that will probably affect your overall outcome.

Nuria Coll Bastus:So the idea is to simplify it so much and this we are working into a. Incorporating a new feature where doctors, when they have the patient recording their laptops or in their computers, they have also already the shortlisted list of trials that they may be eligible. And so this is automatic every 24 hours.

Nuria Coll Bastus:So maybe if your patient doesn't want to go to a trial today, but in six months, relapse from a previous treatment will be a new set of trials that will be available if they want to do that. So that is our vision.

Adam Walker:I love that. That's brilliant.

Adam Walker:As you were talking, I wrote down a little question which I wanted to ask you around health outcomes, and it's a more general point that has come up in, in other conversations I've had with other guests on the podcast.

Adam Walker:It's around how everyone can take ownership for their own healthcare. I'm curious to know what your feelings, what your thoughts are around that as well, because. It shouldn't just be the case that we seek help when things are going wrong for us, when we have an out of range result from our medical report or we have some bloods taken out of the blue, what can people do to secure their health outcomes and be more proactive about that?

Nuria Coll Bastus:So there are research studies and publications that show that actually people that are proactive and taking care of their health tend to have earlier diagnosis, which obviously affect the treatment options, which obviously affect the prognosis and the outcome of their treatments. So I always say to everybody that is close to me that they should.

Nuria Coll Bastus:Be a bit more active, not just relying on the programs from the government to screen every, a number of years for certain things, but if they have the capacity to maybe do additional tests every year, every two years, whatever it takes, uh, whatever makes sense, right? Uh, even if it's privately, I, I know not everybody will have the financials, but at the same time I said, okay, you are, most people go out for dinner.

Nuria Coll Bastus:Once a week and they spend 50, a hundred pounds, maybe you can skip three weekends a, a year and maybe pay for a test that it would be maybe identifying if you have any problem two years down the, uh, before the NHS would be able to do it. So for me, it's always, if you can do, if you can keep reading and learning about your body, about your health, like almost basic, basic, uh, knowledge on, on the set that will.

Nuria Coll Bastus:Basically probably make a, a huge difference on you also, not only on how under the diagnosis and the outcome of your diseases, but also makes you, it'll educate you to have a healthier life that will make you feel better. And so that also is related to quality of life.

Adam Walker:Yeah, I mean, entirely agree with that.

Adam Walker:Uh, I think quality of life measures, they're often there in clinical trial methodologies again. It's much further down the line, isn't it? It's when they're receiving treatment that patients answer. Quality of life measures generally.

Adam Walker:I wonder whether or not clinical net could be implemented on an NHS app or you know, whatever equivalent across Europe in the globe as a front point to just remind people of what's out there, even in a healthy state.

Adam Walker:I think that's the key, isn't it? It's we hope for health, but unfortunately. With age comes comorbidities and things that happen to us, some of which are genetic, which we've, you know, we've touched on with, with your background, but also some of which are environmental. There are many environmental factors these days that are influencing people's health, wellbeing and health outcomes aren't there.

Nuria Coll Bastus:Definitely. Uh, absolutely. And in regards to your point about being implemented through the NHS app we are open to that. We are talking with the NIHR, which also are involved with, providing information about clinical trials to, to the general population. They did say they really like our platform, but obviously these things take time and it needs alignment.

Nuria Coll Bastus:And also, uh. We are at the end of the day, a private organization. So there is also some things to polish in down this line, but we are very open to pro, uh, as to provide our services, uh, to everybody. And going through organizations like the NS definitely will be something that will help raise awareness to everybody.

Adam Walker:I'm really glad, I'm really glad you said that because it was at the forefront of my mind as he was just describing how people are made aware of it. And I think the greatest awareness you can have is just to be reminded all the time, isn't it? Whether it's on the underground, London underground, or wherever you are.

Adam Walker:Buses, there's popups all over the place on every platform that we're looking on in the palm of our hands these days. So I'm sure you're doing all sorts of very clever marketing on, on various different social media platforms. Are you?

Nuria Coll Bastus:We, we are doing, uh, obviously we are still a small and marketing, it's costly.

Nuria Coll Bastus:So we are doing as much as we can and the money that we're raising from investors is mostly dedicated to marketing, to raise awareness.

Adam Walker:I hope that we can get some of those messages out for you from, from the podcast as well.

Adam Walker:So, um, at this point in the conversation, I always like to move to a quick fire round and talk a little bit more about the person behind the person that presents.

Adam Walker:So I wonder, Noria, what is the one piece of advice you would give to your younger self?

Nuria Coll Bastus:I start things younger in the sense that sometimes I hesitated a lot of times to start doing things for fear, for, for fear to, for failure, fear of finances, et cetera. So, but at the same time, I'm very glad that I made that step to, to eventually try this for many things first because. We give opportunity hope to people.

Nuria Coll Bastus:We have the opportunity to improve healthcare and, uh, and general what health in people, but also because I learn a lot and, uh, give a, a little bit more sense of purpose of why we are working right while we are making an effort. So I will say don't be scared and do it sooner.

Adam Walker:Thank you for sharing that.

Adam Walker:I often say, and I've heard it said, failure is data acquisition. So I come, I come back to that point, you know, without failure we don't learn anything, do we? Definitely, I agree with that. What are the top three qualities you value most when building a team?

Nuria Coll Bastus:Motivation not for money, but motivation for making a difference.

Nuria Coll Bastus:Honesty and openness to share when things are going right, but also when things are going well and positivity. Looking always at solutions rather than at problems. I remember when I was doing my. Degree in chemistry. One of the professors told us there are two types of people , in this planet.

Nuria Coll Bastus:Those that create problems and the ones that solve problems. Which one do you want to be? So yeah,

Adam Walker:I can clearly see which one you are in that, by the way. Thank you for that. And what is your favorite thing outside of work

Nuria Coll Bastus:sport? And I sometimes miss having the time to do a sport outside

Adam Walker:any particular sports.

Nuria Coll Bastus:I like any of them. Um, but I have to say I'm not very good with the ones that, uh, involve arms like tennis or basketball. But still, uh, for example I try to spend some time playing paddle tennis, which is a Missy version of, of tennis. But yeah, I will say any type of sport.

Adam Walker:Fabulous. And finally, what is your number one golden rule in life and in business?

Nuria Coll Bastus:Don't give up.

Adam Walker:I am sensing you're not someone that gives up very easily being that solution led person that you are. Nuria.

Adam Walker:This has been a wonderful conversation. I think we've covered all manner of different aspects of your motivation, your drive, the success, and the future plans for Clinical net. I really do wish you very well for that.

Adam Walker:I'd like to thank you for your time today, but also if there are listeners out there who'd like to make contact with you, Nuria, what's the best way of making contact?

Nuria Coll Bastus:The best way probably is to go to the, our website and there is, uh, contact us section where they can write us. And I believe also there is the main contact email address so they can also use that.

Adam Walker:Very good. And as I say, it's been a wonderful conversation today. I wanted to thank you for taking the time, Noria to come on to Pharma Prescribe Today, and thank you for sharing the story of Clinical Net. It's been an absolute delight to get to know you.

Nuria Coll Bastus:Thank you very much for having me. Thanks.